Verquvo · DIN 02537044 · 2.5 mg · tablet
Limited Use, Reason for Use code 685 requiredMarketed · checked November 20, 2026
StatusLimited Use, Reason for Use code 685 required
Write on scriptReason for Use code 685 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 685
Reason for Use code 685
For the treatment of symptomatic chronic heart failure (HF) as an adjunct to standard-of-care therapy in adult patients with reduced ejection fraction who are stabilized after a recent HF decompensation event, if all the following conditions are met:
(a) Left ventricular ejection fraction (LVEF) less than 45%;
(b) New York Heart Association (NYHA) class II to IV symptoms;
(c) HF decompensation event requiring hospitalization within the previous 6 months and/or intravenous diuretic treatment for HF (without hospitalization) within the previous 3 months;
(d) Vericiquat is used in combination with standard-of-care* HF therapy; and
(e) Initiated under the supervision of a prescriber who is experienced in the management of HF.
* Standard-of-care HF therapy includes one medication from each of the following categories, unless there is a contraindication or intolerance:
(a) angiotensin receptor-neprilysin inhibitor (ARNI) or angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB);
(b) beta blocker;
(c) mineralocorticoid receptor antagonist (MRA); and
(d) sodium-glucose cotransporter-2 (SGLT2) inhibitor
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Verquvo · DIN 02537044
Manufacturer: Bayer Inc., Health Care Division; listing date 2024-09-27
Health Canada: Marketed since 2023-09-19 · brand VERQUVO · ATC C01DX22 VERICIGUAT · form Tablet · route Oral · ingredients VERICIGUAT 2.5 MG · company Bayer inc · schedule Prescription
Verquvo: Formulary list price $4.83 per unit (the source does not state the unit; exact figure $4.8300). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02537044)
Source record
DIN 02537044: Verquvo
Raw flags: sec12=Y, sec3=Y
Item: 241200113; group id 373; item number 0888; lccId 00400; manufacturer id BAH
Source form: Tab; strength: 2.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $4.8300; ministry $4.8300
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02537044
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102575
Shortage status: not checked (no credentials)